secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001070081-23-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC reports ~$710M FY2022 total revenue (+30% YoY); guides FY2023 to $940M-$1B
------------------------------------------------------------------------------

- FY2022 unaudited total revenue ~$710M; DMD franchise net product revenue $507M (Translarna $289M, Emflaza $218M).
- Evrysdi collaboration/royalty revenue ~$175M in 2022.
- FY2023 total revenue guidance $940M-$1B; DMD franchise net product revenue $545-$565M.
- Non-GAAP R&D and SG&A expense guided to $890-$940M; up to $80M milestone payments.
- Three registration-directed trial results expected in 2023: sepiapterin (PKU), vatiquinone (MDAS, FA); Upstaza BLA submission H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000004/0001070081-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000004/tmb-20230109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer